Efficacy and safety of the SoniCracker intravascular lithotripsy device for severely calcified coronary lesions: the LEAD-FIM study from China Authors: Haiwei Liu, Jiancheng Xiu, Qin Qin, Ziliang Bai, Qian Tong, Shaobin Jia, Ping Zhang, Jun Zhang, Zhixiong Zhong, Wei Liu, Yong He, Quanmin Jing, Yaling Han Published: 2025 ABSTRACT BackgroundCalcified lesions represent a key challenge in percutaneous coronary intervention (PCI). In recent years, intravascular lithotripsy (IVL) has emerged as a safe and effective adjunctive therapy for severely calcified lesions before stenting implantation. In the present study, we investigated the safety and efficacy of a novel coronary IVL system in patients with severely calcified lesions.MethodsThe LEAD-FIM study was a prospective, multicenter, single-arm trial in China. Patients with severely calcified lesions and a clinical indication for PCI with vessel preparation for DES implantation using IVL. The primary endpoint was procedural success, which was defined as residual stenosis ≤ 30% following successful stent placement and the absence of major adverse cardiac event (MACE, including cardiac death, myocardial infarction, or target vessel revascularization) up to 7 days post-procedure. The primary endpoint assessed against performance goals derived from major published registries on Shockwave IVL. A subgroup analysis using optical coherence tomography was carried out to evaluate the morphology of calcification before and after IVL treatment, as well as post-stent.ResultsFrom February to April 2023, a total of 184 patients with severely calcified lesions at 11 sites were enrolled. The target lesions were predominantly in the left anterior descending artery (77.2%) and the mean diameter stenosis was 87.6%±6.6%. Procedure success was observed in 96.7% (178/184) of patients (95%CI: 94.2%-99.3%), which significantly surpassed the prespecified performance goal of 85.0% (p < 0.001). All patients met the criteria of angiographic success and 6 (3.3%) patients occurred in-hospital MACE event. The rate of 30-day and 180-day MACE was 3.8% (7/184) and 4.9% (9/184), respectively. In the OCT sub-study population, minimum lumen area increased after IVL by 1.22 ± 0.87 mm² and by an additional 2.54 ± 1.73 mm² post stenting with overall stent expansion of 85.3 ± 17.1% at the site of maximal calcification. No serious adverse events associated with the device were documented. The rates of target lesion failure at 1- and 6-month were 3.3% and 4.4%, respectively.ConclusionsThe novel IVL system could promote stent delivery and achieve optimized stent expansion among patients with severely calcified coronary lesions.Trial registrationThis trial was registered in the clinicaltrials.gov (URL: https://www.clinicaltrials.gov; Unique identifier: NCT05649488) on 28th November 2022.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12872-025-05447-4. Introduction With the global burden of aging population and the prevalence of cardiometabolic comorbidities rising, calcified lesions are present in approximately 25%−50% of coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) [1, 2]. These calcified lesions substantially increase the technical complexity of the PCI procedures. Moreover, inadequate modification of calcification heightens the risk of vascular complications, thereby adversely affecting both short- term and long-term prognosis of these patients [3]. To address these challenges, various plaque modification techniques have been developed over the years [4]. These include high-pressure non-compliant balloon angioplasty, specialized balloons (such as scoring, cutting, and ultra-high-pressure balloons), and atheroablative technologies (rotational or orbital atherectomy, and laser ablation). However, these approaches have notable limitations, like a steep learning curve for atherectomy and risks of complications like perforation, slow flow, or no reflow phenomena [5, 6]. Intravascular lithotripsy (IVL) has recognized as a novel adjunctive therapeutic approach for severely calcified lesions prior to drug-eluting stent (DES) in recent year [7–9]. The IVL system integrates specialized emitters within a balloon catheter to convert electrical pulses into high-intensity acoustic energy, transmitted via balloon fluid to the vascular wall. Mechanistically, these shockwaves induce molecular-level calcium fracture within calcified plaques, reducing plaque rigidity and enhancing vascular compliance to optimize stent deployment [10, 11]. In this study, we investigate the effectiveness and safety of a novel coronary IVL device (SoniCracker™), which has a unique convex point positive electrode designed to provide more uniform pressure distribution, a double-layer balloon design to increase puncture resistance and a wider range of sizes compared to currently available devices, for severely calcified lesions prior to DES implantation. Methods Study design and participants The LEAD-FIM trial was a prospective, multicenter, single-arm trial carried out at 11 high-volume PCI sites across China. The organizational structure and participating sites of LEAD-FIM trial are detailed in Supplemental Appendix 1. Patients aged 18 to 80 years presenting with symptomatic ischemia, stable or unstable angina, or myocardial infarction (MI) for more than 7 days were eligible if they had severely calcified de novo coronary artery lesions with diameter stenosis ≥ 70% or (≥ 50% with evidence of ischemia), which were appropriate for IVL and had a length ≤ 40 mm, with reference vessel diameter (RVD) ranging from 2.25 mm to 4.0 mm. The main exclusion criteria included a plan to receive atherectomy, modified balloon (e.g. cutting, scoring balloon) treatment; New York Heart Association functional class III or IV; or left ventricular ejection fraction < 35%. The main angiographic exclusion included an ostial location (in the left anterior descending [LAD], left circumflex [LCX], or right coronary artery [RCA], within 5 mm of ostium), an unprotected left main lesion; prior stent implantation within 10 mm of the target lesion; a severe dissection (Type D to F) in the target vessel; an aneurysm within 10 mm of the lesion in target vessel; and thrombus within the target lesion. A summary of inclusion and exclusion criteria for the present study is presented in Supplementary Appendix 2. A pre-specified subgroup using optical coherence tomography (OCT) imaging was planned to analyze the changes in calcified lesions prior to and after lithotripsy, as well as following the final stent implantation. The study complied with the Declaration of Helsinki, and the protocol was approved by institutional ethics committees at each participating center (detailed in Supplemental Appendix 1). All patients provided written informed consent prior to participation in the trial. Study devices and procedures The SoniCracker™ Coronary IVL Therapy Device is a shock wave lithotripsy device designed to work in conjunction with a SoniCracker™ SingleUse Coronary IVL Catheter. When the catheter is positioned at calcified stenoses (including those where balloon expansion and/or stent deployment is hindered) that are difficult to treat, the therapy device delivers electrical energy through wires to electrodes embedded within the catheter. These electrodes then convert the electrical energy into sound energy within the balloon, effectively fracturing the calcified lesions. This process enables balloon dilatation of the stenosed coronary artery lesions at lower balloon inflation pressures. The full details regarding the study devices are presented in Supplemental Appendix 3. Endpoints and definitions The primary effectiveness endpoint was procedural success, defined as a residual in-stent stenosis ≤ 30% following stent implantation based on quantitative coronary angiography (QCA) and without in-hospital major adverse cardiac events (MACEs, up to 7 days after procedure). Secondary effectiveness endpoint included angiographic success, which was defined as a residual in-stent stenosis ≤ 30% after stent implantation based on QCA and without serious angiographic complications. Safety endpoints comprised device success, serious angiographic complications, MACEs at 30 days and 6 months, as well as target lesion failure (TLF) at 30 days and 6 months. MACE was defined as a composite of cardiac death, MI, and/or target vessel revascularization. Serious angiographic complications included severe dissection [type D to F], perforation, abrupt closure, and/or persistent slow flow or no reflow phenomena. TLF was defined as a composite endpoint involving cardiac death, target vessel MI, and target vessel revascularization. Periprocedural MI was defined as a peak level of creatine kinase-MB greater than 3 times the upper reference limit, with or without new pathological Q waves post procedure [12]. For spontaneous MI, the Fourth Universal Definition of MI was adopted [13]. Angiograms were analyzed by an independent intravascular imaging core laboratory (JetMed Co., Ltd), and all adverse events were adjudicated by a clinical events committee. Severe calcification is characterized by observed radiopaque densities in the absence of cardiac motion before contrast injection, with involvement of both sides of the arterial wall [4]. In the OCT subgroup, secondary endpoints were post-procedural minimum stent area (MSA), acute gain of lumen area, minimum stent lumen diameter (MLD), acute gain rate, and stent expansion and stent struts malapposition. MSA was measured using an automated software (QIvus version 3.1 Medis). Stent expansion was defined as MSA/[(proximal + distal reference area)/2] × 100 MSA/[(proximal + distal reference area)/2] × 100. Statistical analysis According to the ORBIT II study [14], the procedural success rate was 88.9%, and the lower limit of the 95% confidence interval (CI) was 85.5%. In the DISRUPT CAD III study [15], the procedural success rate reached 92.4%, with the lower limit of the 95% CI being 90.2%. Additionally, the procedural success rate of 89.2% from BENELUX-IVL registry were also consulted [16]. Thus, given a performance target of 85.0% and an estimated procedural success rate for lithotripsy of 92.4%, 156 patients were required to achieve a one-sided significance level (α) of 0.025 and a type II error probability (β) of 0.2. Allowing for an attrition rate of 15%, 184 patients were required to be enrolled. Continuous variables are reported as mean ± standard deviation, whereas categorical variables are reported as frequency (percentage). The primary effectiveness endpoint was expressed as a point estimate together with 95% confidence interval (CI) for comparison with the predefined performance goal. The paired t test was employed to compare continuous variables measured before and after treatment in the same patient. Unless otherwise specified, a 2-sided P value less than 0.05 was considered to denote statistical significance. Statistical analysis was conducted using SAS version 9.4 (SAS Institute). Results The flowchart of the study is presented in Fig. 1. A total of 184 patients were enrolled from February 2023 to April 2023. Of these, 2 patients were excluded from per protocol set, one for using cutting balloon during procedure and the other one for a confirmed malignancy diagnosis. Fig. 1Flowchart of study Flowchart of study Baseline characteristics and procedural information Tables 1 and 2 display the baseline clinical characteristics and procedural details. Enrolled patients had a mean age of 64.1 ± 7.5 years, and 65.2% were male. Seventy-seven patients (41.9%) had diabetes, and 126 (68.5%) had hypertension. A total of 156 patients (84.8%) underwent treatment for unstable angina, 2 (1.1%) for asymptomatic myocardial ischemia, 17 (9.2%) for stable angina, 11 (6.0%) for acute MI, and 13 (7.1%) for old MI. Table 1Baseline clinical characteristicsPatient characteristicN = 184Age, years61.1 ± 7.5Sex, n (%) Male120 (65.2%) Female64 (34.8%)Medical history, n (%) Hypertension126 (68.5%) Diabetes77 (41.8%) Hyperlipidaemia62 (33.7%) Previous MI35 (19.0%) Previous PCI79 (42.9%) Previous stroke37 (20.1%)Smoking, n (%) Current51 (27.7%) Former32 (17.4%) Never101 (54.9%)Clinical diagnoses, n (%) Asymptomatic myocardial ischemia2 (1.1%) Stable angina17 (9.2%) Unstable angina156 (84.8%) NSTEMI6 (3.3%) STEMI5 (2.7%) Old myocardial infarction13 (7.1%) LVEF, %61.8 ± 7.4 Table 1Baseline clinical characteristicsPatient characteristicN = 184Age, years61.1 ± 7.5Sex, n (%) Male120 (65.2%) Female64 (34.8%)Medical history, n (%) Hypertension126 (68.5%) Diabetes77 (41.8%) Hyperlipidaemia62 (33.7%) Previous MI35 (19.0%) Previous PCI79 (42.9%) Previous stroke37 (20.1%)Smoking, n (%) Current51 (27.7%) Former32 (17.4%) Never101 (54.9%)Clinical diagnoses, n (%) Asymptomatic myocardial ischemia2 (1.1%) Stable angina17 (9.2%) Unstable angina156 (84.8%) NSTEMI6 (3.3%) STEMI5 (2.7%) Old myocardial infarction13 (7.1%) LVEF, %61.8 ± 7.4 Baseline clinical characteristics Table 2Angiographic and procedural characteristicsN = 184Vascular access, n (%) Radial169 (91.85%) Femoral14 (7.61%) Others1 (0.54%)Target vessel, n (%) Left anterior descending artery142 (77.17%) Circumflex artery4 (2.17%) Right coronary artery37 (20.11%) Others1 (0.54%) Reference vessel diameter, mm3.03 ± 0.42Minimum lumen diameter, mm Diameter stenosis, %87.58 ± 6.62 Lesion length, mm28.18 ± 8.54 Predilatation, n (%)129 (70.11%) 1 balloon104/129 (80.62%) ≥2 balloons25/129 (19.38%) Maximum IVL inflation pressure, atm8.0 ± 0.2 Number of lithotripsy catheters1.1 ± 0.2 Number of pulses50.9 ± 23.6 Number of stents implanted1.6 ± 0.6 Total stent length per patient, mm27.46 ± 7.06 Table 2Angiographic and procedural characteristicsN = 184Vascular access, n (%) Radial169 (91.85%) Femoral14 (7.61%) Others1 (0.54%)Target vessel, n (%) Left anterior descending artery142 (77.17%) Circumflex artery4 (2.17%) Right coronary artery37 (20.11%) Others1 (0.54%) Reference vessel diameter, mm3.03 ± 0.42Minimum lumen diameter, mm Diameter stenosis, %87.58 ± 6.62 Lesion length, mm28.18 ± 8.54 Predilatation, n (%)129 (70.11%) 1 balloon104/129 (80.62%) ≥2 balloons25/129 (19.38%) Maximum IVL inflation pressure, atm8.0 ± 0.2 Number of lithotripsy catheters1.1 ± 0.2 Number of pulses50.9 ± 23.6 Number of stents implanted1.6 ± 0.6 Total stent length per patient, mm27.46 ± 7.06 Angiographic and procedural characteristics The target lesions were predominantly in the LAD (77.2%) and the mean diameter stenosis was 87.6 ± 6.6%. All lesions were severely calcified. The mean baseline RVD was 3.0 ± 0.4 mm, and the length of lesion was 28.2 ± 8.5 mm. A total of 129 patients (70.1%) underwent target lesion pre-dilatation prior to IVL without residual stenosis ≥ 30%, dissection of type C or worse, and TIMI flow grade below 3. Of these patients, 80.6% required only one pre-dilation balloon. The IVL balloon catheter was successfully delivered in all procedures with a mean of 50.9 ± 23.6 pulses. Stents were implanted in all 184 patients (100.0%) post-IVL. The details of IVL devices are shown in Supplementary Appendix 4. The baseline characteristics, procedural details, and procedural success rates were comparable between the non-OCT group and the OCT group are shown in Supplementary Appendix 5. Clinical outcomes Procedure success was observed in 96.7% (178/184) of patients (95%CI: 94.2%−99.3%) in full analysis set. This result significantly exceeded the pre-specified performance goal of 85.0% (P < 0.001). Angiographic success (residual stenosis ≤ 30% without serious procedure-related complications) was achieved in all patients. Besides, 6 patients (3.3%) occurred in-hospital MACE, including an MI incidence of 2.7% (5/184) and a TVR incidence of 0.5% (1/184). In the per-protocol set, procedural success was achieved in 96.7% (176/182) of the per-protocol population (95% CI: 93.0%−98.8%), which also met the pre-specified performance goal (P < 0.001). The rate of 30-day and 180-day MACE was 3.8% (7/184) and 4.9% (9/184), respectively. The rate of 30-day and 180-day TLF was 3.3% (6/184) and 4.3% (8/184), respectively (Table 3). Table 3Clinical and angiographic outcomesFAS(N = 184)PPS(N = 182)Procedural success, n (%)178 (96.7%)176 (96.7%)In-stent residual stenosis ≤ 30%184 (100.0%)182 (100.0%)In-hospital MACE6 (3.3%)6 (3.3%)Cardiac death0 (0.0%)0 (0.0%)MI5 (2.7%)5 (2.7%)TVR1 (0.5%)1 (0.5%)Angiographic success, n (%)184 (100.0%)182 (100.0%)In-stent residual stenosis ≤ 30%184 (100.0%)182 (100.0%)Severe angiographic complications0 (0.0%)0 (0.0%)Type D-F dissection0 (0.0%)0 (0.0%)Perforation0 (0.0%)0 (0.0%)Abrupt closure0 (0.0%)0 (0.0%)Slow flow or no-reflow0 (0.0%)0 (0.0%)MACE 1-month7 (3.8%)7 (3.8%) Cardiac death0 (0.0%)0 (0.0%) MI5 (2.7%)5 (2.7%) TVR2 (1.1%)2 (1.1%) 6-month9 (4.9%)9 (4.9%) Cardiac death1 (0.5%)1 (0.5%) MI5 (2.7%)5 (2.7%) TVR3 (1.6%)3 (1.6%)TLF 1-month6 (3.3%)6 (3.3%) Cardiac death0 (0.0%)0 (0.0%) MI5 (2.7%)5 (2.7%) TLR1 (0.5%)1 (0.5%) 6-month8 (4.3%)8 (4.3%) Cardiac death1 (0.5%)1 (0.5%) MI5 (2.7%)5 (2.7%) TLR2 (1.1%)2 (1.1%) Device success184 (100.0%)182 (100.0%) Table 3Clinical and angiographic outcomesFAS(N = 184)PPS(N = 182)Procedural success, n (%)178 (96.7%)176 (96.7%)In-stent residual stenosis ≤ 30%184 (100.0%)182 (100.0%)In-hospital MACE6 (3.3%)6 (3.3%)Cardiac death0 (0.0%)0 (0.0%)MI5 (2.7%)5 (2.7%)TVR1 (0.5%)1 (0.5%)Angiographic success, n (%)184 (100.0%)182 (100.0%)In-stent residual stenosis ≤ 30%184 (100.0%)182 (100.0%)Severe angiographic complications0 (0.0%)0 (0.0%)Type D-F dissection0 (0.0%)0 (0.0%)Perforation0 (0.0%)0 (0.0%)Abrupt closure0 (0.0%)0 (0.0%)Slow flow or no-reflow0 (0.0%)0 (0.0%)MACE 1-month7 (3.8%)7 (3.8%) Cardiac death0 (0.0%)0 (0.0%) MI5 (2.7%)5 (2.7%) TVR2 (1.1%)2 (1.1%) 6-month9 (4.9%)9 (4.9%) Cardiac death1 (0.5%)1 (0.5%) MI5 (2.7%)5 (2.7%) TVR3 (1.6%)3 (1.6%)TLF 1-month6 (3.3%)6 (3.3%) Cardiac death0 (0.0%)0 (0.0%) MI5 (2.7%)5 (2.7%) TLR1 (0.5%)1 (0.5%) 6-month8 (4.3%)8 (4.3%) Cardiac death1 (0.5%)1 (0.5%) MI5 (2.7%)5 (2.7%) TLR2 (1.1%)2 (1.1%) Device success184 (100.0%)182 (100.0%) Clinical and angiographic outcomes OCT substudy analysis Among all the participants, 72 (39.1%) underwent OCT during the procedure. The mean post-procedural MSA was 5.30 ± 1.74 mm2 with MLD of 2.56 ± 0.42 mm in full analysis set and per-protocol set. At the MLA site, the pre-lithotripsy lumen area averaged 2.00 ± 1.04 mm2, which increased to 3.19 ± 1.18 mm2 following IVL (Fig. 2). Moreover, the mean acute gain in luminal area was 3.29 ± 1.45 mm2, and the mean acute gain rate reached 201 ± 120%. Stent expansion was 73.94 ± 14.54% at the MLA site, with proximal and distal reference vessels of 8.35 ± 2.46 mm2 and 5.80 ± 1.95 mm2, respectively. The rate of stent malapposition was 22.2% (16/72). Fig. 2Cumulative frequency distribution curves derived from optical coherence tomography for minimal lumen area Cumulative frequency distribution curves derived from optical coherence tomography for minimal lumen area The IVL procedure led to significant calcification fractures in 81.2% (56/69) of the patients, achieving a maximum depth of 0.70 ± 0.17 mm and a maximum width of 0.44 ± 0.16 mm. At the location of maximal calcification, the luminal area before lithotripsy was 2.28 ± 1.05 mm2, rising to 3.48 ± 1.14 mm2 after IVL (paired t test P < 0.001) and further to 6.08 ± 1.91 mm2 following stent implantation (paired t test P < 0.001) (Table 4). Table 4OCT measurementsFAS(N = 72) Post-procedural Minimum stent area, mm25.30 ± 1.74 Minimum stent lumen diameter, mm2.56 ± 0.42 Acute gain of lumen diameter, mm0.98 ± 0.57 Acute gain of lumen area, mm23.29 ± 1.45 Acute gain rate of lumen area, %201 ± 120 Stent expansion, %73.94 ± 14.54 Malapposition rate of stent struts, %16 (22.22%)Morphology Concentric34 (47.22%) Eccentric38 (52.78%) OCT calcium score3.80 ± 0.52 00 (0.00%) 10 (0.00%) 25 (6.94%) 31 (1.39%) 466 (91.67%) At the site of MLA Pre-IVL stenosis, %71.76 ± 11.47 Post-IVL stenosis, %53.84 ± 13.91 Pre-IVL calcium angle, °279.74 ± 86.55 Post-IVL calcium angle, °246.64 ± 72.97 Pre-IVL calcium thickness, mm0.77 ± 0.16 Post-IVL calcium thickness, mm0.69 ± 0.13 Pre-IVL minimum lumen area, mm22.00 ± 1.04 Post-IVL lumen area, mm23.19 ± 1.18 At the site of maximal calcification Pre-IVL lumen area, mm22.28 ± 1.05 Post-IVL lumen area, mm2*3.48 ± 1.14 Post-stenting luminal area, mm2*6.08 ± 1.91 Pre-IVL calcium angle, °304.50 ± 68.65 Post-IVL calcium angle, °266.66 ± 67.11 Pre-IVL calcium thickness, mm0.82 ± 0.16 Post-IVL calcium thickness, mm0.71 ± 0.14 Stent expansion, %85.33 ± 17.14 Calcification fractures N = 69 Yes56 (81.16%) No13 (18.84%) Maximum depth of fracture, mm0.70 ± 0.17 Maximum width of fracture, mm0.44 ± 0.16 Table 4OCT measurementsFAS(N = 72) Post-procedural Minimum stent area, mm25.30 ± 1.74 Minimum stent lumen diameter, mm2.56 ± 0.42 Acute gain of lumen diameter, mm0.98 ± 0.57 Acute gain of lumen area, mm23.29 ± 1.45 Acute gain rate of lumen area, %201 ± 120 Stent expansion, %73.94 ± 14.54 Malapposition rate of stent struts, %16 (22.22%)Morphology Concentric34 (47.22%) Eccentric38 (52.78%) OCT calcium score3.80 ± 0.52 00 (0.00%) 10 (0.00%) 25 (6.94%) 31 (1.39%) 466 (91.67%) At the site of MLA Pre-IVL stenosis, %71.76 ± 11.47 Post-IVL stenosis, %53.84 ± 13.91 Pre-IVL calcium angle, °279.74 ± 86.55 Post-IVL calcium angle, °246.64 ± 72.97 Pre-IVL calcium thickness, mm0.77 ± 0.16 Post-IVL calcium thickness, mm0.69 ± 0.13 Pre-IVL minimum lumen area, mm22.00 ± 1.04 Post-IVL lumen area, mm23.19 ± 1.18 At the site of maximal calcification Pre-IVL lumen area, mm22.28 ± 1.05 Post-IVL lumen area, mm2*3.48 ± 1.14 Post-stenting luminal area, mm2*6.08 ± 1.91 Pre-IVL calcium angle, °304.50 ± 68.65 Post-IVL calcium angle, °266.66 ± 67.11 Pre-IVL calcium thickness, mm0.82 ± 0.16 Post-IVL calcium thickness, mm0.71 ± 0.14 Stent expansion, %85.33 ± 17.14 Calcification fractures N = 69 Yes56 (81.16%) No13 (18.84%) Maximum depth of fracture, mm0.70 ± 0.17 Maximum width of fracture, mm0.44 ± 0.16 OCT measurements Discussion The LEAD-FIM study has evaluated the efficacy and safety of a novel IVL system for lesion preparation in severely calcified coronary stenoses prior to DES implantation, in a multicenter single-arm study of 184 patients with 6-month clinical follow-up. This study showed that coronary IVL treatment achieved the primary effectiveness endpoints, with a procedural success rate of 96.7%. In addition to being well tolerated, coronary IVL prior to DES implantation was associated with a low rate of 6-month clinical endpoints, including MACE, TLF, and their individual components. Furthermore, OCT results showed that over 80% of patients had a multi-planar and longitudinal calcium fractures following IVL, accompanied excellent stent expansion. The prevalence of calcified lesions is reported to be approximately half of coronary lesion by angiography in routine clinical practice. The figure rises significantly to 76% to 83% when assessed with intracoronary imaging techniques [1]. The presence of coronary artery calcification is associated with elevated risks of complications during the procedure, including dissections and perforations. Furthermore, calcified lesions pose significant challenges to device delivery and optimal stent deployment, frequently resulting in mechanical failures (stent underexpansion or malapposition) and subsequently adverse events over the long term, such as recurrent revascularization and stent thrombosis [17]. Despite advancements in contemporary plaque modification techniques, the results of calcified lesions PCI frequently continue to yield suboptimal clinical outcomes. The IVL devices employ acoustic pressure waves to effectively break down subendothelial calcification and calcified nodules, thereby enabling remarkable lumen area gains and optimal stent expansion, which has been clinically demonstrated to offer efficacy and safety in interventions for calcified coronary lesions [12]. Recently, a series of trials have been conducted to validate the effectiveness of the IVL system in patients with calcified coronary lesions. Compared with previous studies [12, 18, 19], the present LEAD-FIM trial demonstrated a comparable or higher procedural success rate, with all patients achieving in-stent residual stenosis ≤ 30% and only 6 cases of MACE during hospitalization. Substantial improvements were observed at the location of maximal calcification after IVL. Specifically, the calcium angle decreased from 304.50° to 266.66°, the calcium thickness was reduced from 0.82 mm to 0.71 mm, and the lumen area increased from 2.28 mm² to 3.48 mm². Furthermore, over 80% of cases exhibited significant calcific fractures after the IVL procedure, with a maximum depth of 0.70 mm and a maximum width of 0.44 mm. These changes are conducive to subsequent stent implantation and the further increase of stent lumen area. Benefiting from technological advancements, including the 18 distinct balloon sizes (with lengths of 10 mm and 15 mm, a diameter range of 2.0 mm to 4.0 mm), as well as a rated burst pressure of 20 atm, the present IVL device can be easily delivered and facilitates optimized stent expansion in complex lesions. Notably, the availability of a 2.0 mm balloon size specifically addresses the unmet need for IVL in small vessels, thereby overcoming a key limitation of other IVL systems, which are available in sizes of 2.5 mm and larger. Regarding clinical outcomes, the 1-month and 6-month MACEs rates were consistent with in-hospital MACE rate in the full analysis set and per-protocol set. Furthermore, the low incidence of TLF further corroborates the favorable safety profile of IVL device. A recent post hoc analysis evaluated the function of intravascular imaging in guiding and optimizing DES implantation for moderately or severely calcified coronary lesions [20]. The findings revealed that optical coherence tomography (OCT) guidance was linked with a larger minimal stent area post-PCI and a lower 2-year TVF rate. In addition, the CALIPSO randomized trial demonstrated that OCT guidance yielded superior stent implantation outcomes compared with angiographic guidance, with no added safety concerns in calcified lesions PCI [21]. As a novel calcium modification strategy, there was limited evidence to compare IVL and previous lesion preparatory techniques. The ROLLER COASTR-EPIC22 randomized trial show that IVL was noninferior to rotational atherectomy with respect to stent expansion (86.4% vs. 85.6%) and similar MSA (5.5 ± 2.1 mm2 vs. 5.4 ± 1.8 mm2) as assessed by OCT [22]. Additional studies are warranted to determine the advantages of integrating calcium modification techniques and intravascular imaging for enhancing clinical outcomes in patients with severely calcified coronary lesions. Moreover, this study was conducted solely in a Chinese population. While large IVL registries, such as BENELUX-IVL [23–25] and REPLICA [26], have demonstrated favorable safety and efficacy profiles with high procedural success and low adverse event rates, our findings warrant validation in more diverse cohorts involving multi-ethnic and or anatomical populations. Finally, it is also anticipated that the growing availability of multiple IVL devices will foster market competition, which may drive down procedural costs and enhance the cost-effectiveness of this treatment. Limitations This trial has several limitations. First, the present study is a single-arm design with an objective performance criteria framework. Consequently, the present study was unable to conduct direct comparative analyses between IVL and other calcium-modifying devices (e.g., atherectomy or specialty balloons), as the study prioritized initial safety and performance over head-to-head comparisons. Notably, the present study showed a rate of procedural success and short- and long-term MACE rates comparable to previous studies, suggesting that IVL approach could serve as an adjunctive therapy prior to DES implantation for severely calcified lesions. Second, the study was designed to assess the primary endpoint of procedural success, rendering it underpowered to evaluate the clinical outcomes. More studies with a large sample size are required to validate the long-term outcomes of IVL. Third, although intracoronary imaging is recommended to guide in complex PCI [27], OCT assessment was not routinely performed in this study. Fourth, Given the first-in-human nature of this study, which prioritized patient safety and procedural standardization, high-risk patients were excluded. Further studies are warranted to confirm the high procedural success rate in unselected real-world populations. Fifth, the definition of severely calcified lesions adopted in this study based on coronary angiography, which might not fully align with OCT assessments. Nonetheless, the high OCT calcium scores1 observed in the OCT subgroup (mean ± SD: 3.80 ± 0.52), with 91.7% of patients scoring 4 points, support the characterization of this cohort as a heavily calcified population [28]. Conclusions This present study demonstrates that a novel coronary IVL device could facilitate stent delivery and optimize stent expansion prior to stent implantation in severely calcified coronary stenoses. Additional confirmatory evidence is required to determine the durability of clinical benefits from IVL compared with other calcium-modifying devices. Supplementary Information Supplementary Material 1 Supplementary Material 1